Article Versions Notes

Kanacher T, Sjögren E, Korell J, Plan EL, Gómez-Mantilla JD, Ince I. Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption. Pharmaceutics. 2025; 17(3):314. https://doi.org/10.3390/pharmaceutics17030314

Kanacher, Tobias, Erik Sjögren, Julia Korell, Elodie L. Plan, Jose David Gómez-Mantilla, and Ibrahim Ince. 2025. "Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption" Pharmaceutics 17, no. 3: 314. https://doi.org/10.3390/pharmaceutics17030314

Kanacher, T., Sjögren, E., Korell, J., Plan, E. L., Gómez-Mantilla, J. D., & Ince, I. (2025). Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption. Pharmaceutics, 17(3), 314. https://doi.org/10.3390/pharmaceutics17030314